Highlights

  • Nova Eye Medical is expanding global surgeon adoption of canaloplasty microcatheters used to treat open-angle glaucoma.
  • iTrack glaucoma consumable scale is the commercial engine, because each procedure uses a disposable device.
  • 360-degree canaloplasty viscodilation treats the eye's natural drainage pathway along its full circumference, helping fluid leave the eye.
  • Ophthalmic surgical device Cash Flow depends on how many surgeons adopt and repeat the procedure.

Glaucoma damages vision when fluid cannot drain from the eye. Nova Eye Medical (ASX:EYE) supplies a microcatheter that opens the drainage pathway through 360-degree canaloplasty, and it is working to put the technique into more surgeons' hands worldwide.

How the Procedure Works

Canaloplasty uses a microcatheter to treat the eye's natural drainage channel. Viscodilation involves introducing a viscous material to widen it, helping fluid drain and lowering pressure inside the eye.

About the Company

Nova Eye Medical develops ophthalmic surgical devices. Its iTrack microcatheter is the consumable used in canaloplasty to treat open-angle glaucoma.

Surgeon Adoption

Management is expanding global surgeon adoption. Surgeons need Training and confidence in a technique, so each new adopter represents a long-term driver of procedures.

Consumable Scale

Each procedure uses a single-use device, so growth in surgeon numbers and procedure volumes drives repeat sales and builds cash generation.

Sector Context

Open-angle glaucoma is the most common form of the disease, and ageing populations increase the number of patients needing treatment.

What to Watch

Surgeon numbers, procedure volumes and consumable sales will show how widely the technique is spreading.

Risks to Watch

Alternative glaucoma treatments exist, and adoption depends on clinical evidence and reimbursement. Announcements on the ASX will show how procedure volumes develop.